



# Actinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations

- *Actimab-MDS to be featured in a Product Theater on February 24<sup>th</sup>*
- *Members of Actinium's executive and clinical development teams to participate in conference activities and extend the visibility of the Company's myeloablative drug candidates, Iomab-B and Actimab-MDS, to the bone marrow transplant community*
- *BMT Tandem Meetings being held February 21-25, 2018, in Salt Lake City, Utah*

**NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) --** **Actinium Pharmaceuticals, Inc.** (NYSE American:ATNM) ("Actinium" or "the Company") announced today that representatives from the Company's executive and clinical development teams will be attending the BMT Tandem Meetings, the combined annual meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). The conference is being held February 21 through February 25, 2018, at the Salt Palace Convention Center in Salt Lake City, Utah.

Actinium's planned Phase 2 trial for Actimab-MDS will be highlighted in the Company's Product Theater, Actimab for CD33 Expressing Hematologic Malignancies, which will feature Dr. Sergio Giralt, Chief, Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center and Dr. Koen van Besien, Director, Stem Cell Transplant Program at Weill Cornell Medical Center. The planned Phase 2 trial for Actimab-MDS will study Actinium's anti-CD33-actinium-225 antibody radio-conjugate (ARC) as a myeloablative agent prior to a bone marrow transplant for patients with high-risk myelodysplastic syndrome (MDS) with a p53 genetic mutation. Actinium will be conducting an investigator meeting with representatives from current and prospective clinical trial sites from the Company's pivotal Phase 3 SIERRA trial for Iomab-B. Also, Actinium will formally meet with the Iomab-B Scientific Advisory Board (SAB) to discuss the ongoing SIERRA trial and other initiatives in improved myeloablation.

Dr. Mark Berger, Chief Medical Officer of Actinium said, "With our mission at Actinium to

improve the pathway for patients undergoing bone marrow transplants, the annual BMT Tandem Meetings is a critical forum that enables us to meet with Key Opinion Leaders (KOLs) in the area of bone marrow transplant medicine to share our latest research findings and learn from others. Our attendance at this event offers a rich opportunity to gain insight into the latest developments in our field of science. We are very much looking forward to our investigator and SAB meetings that will provide us with the opportunity to further highlight Iomab-B's highly differentiated profile and discuss certain aspects of the SIERRA trial such as our recent protocol amendment, crossover rates and case studies with representatives from leading bone marrow transplant centers."

The BMT Tandem Meetings include an exciting scientific program that addresses state-of-the-art issues in bone marrow transplant. Meeting attendees include investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, administrators and allied health professionals seeking to benefit from its hematopoietic cell transplantation focused program.

Sandesh Seth, Actinium's Executive Chairman said, "Our Iomab-B and Actimab-MDS drug candidates are critical elements to our overall strategy at Actinium to improve transplant access and outcomes via improved myeloablation. We anticipate this year's conference to be even more productive for us than last year as we are attending as the only company with a multi-disease, multi-product pipeline focused on improved myeloablation."

### **About BMT Tandem Meetings**

Annually, the BMT Tandem Meetings are the largest gathering in North America of worldwide experts in blood and marrow transplant patient care, clinical investigation and laboratory research. Over 3,000 transplant physicians in over 500 transplant centers from >50 countries participate in the CIBMTR. The ASBMT has a membership of over 2,300 clinicians and researchers. By combining our meetings, we expect over 3,200 participants at next year's meetings representing more than 50 countries, with approximately 20% coming from outside the United States.

### **About Actinium Pharmaceuticals, Inc.**

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. Our targeted therapies have demonstrated the potential to result in significantly improved access to bone marrow transplant with better outcomes, namely increased marrow engraftment and survival. Our targeted therapies are ARC's or Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. We have four clinical trials based on our AWE or Actinium Warhead Enabling Technology Platform that utilizes the isotope Actinium-225 (Ac <sup>225</sup>) which emits alpha particles. In addition, our most advanced product candidate, Iomab-B, an ARC developed by the Fred Hutchinson Cancer Research Center, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131. We are currently conducting a pivotal Phase 3 trial of Iomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow transplant is a potentially curative treatment for patients with

AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as certain blood disorders. Iomab-B has been tested in several of these other cancers with over five hundred patients treated in several Phase 1 and 2 trials with promising results. Upon successful completion of our Phase 3 clinical trial for Iomab-B we intend to submit this candidate for marketing approval in the U.S. and European Union where it has been designated as an Orphan Drug. We are also developing a potentially best in class CD33 program using an ARC comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Our most advanced CD33 program candidate, Actimab-A, is currently in a Phase 2 clinical trial for patients advanced over the age of 60 who are newly diagnosed with AML and ineligible for standard induction chemotherapy. Actimab-A also has Orphan Drug designation in the US and EU. Actimab-M, our second CD33 program ARC, is being studied in a Phase 1 trial for patients with refractory multiple myeloma. Actinium is also planning a Phase 2 trial for Actimab-MDS, our third CD33 program candidate, as a conditioning regimen prior to a bone marrow transplant for patients with MDS that have a p53 genetic mutation. Our Phase 1 trial studying Actimab-A with CLAG-M is our fourth CD33 program clinical trial for patients with relapsed or refractory AML. Our AWE or Actinium Warhead Enabling Technology Platform, originally developed in conjunction with Memorial Sloan Kettering Cancer Center, is focused on leveraging Actinium's know how and intellectual property to create additional ARC drug candidates by labeling <sup>225</sup>Ac to targeting moieties that we will either progress in clinical trials ourselves or out-license.

More information is available at [www.actiniumpharma.com](http://www.actiniumpharma.com) and our Twitter feed @ActiniumPharma, [www.twitter.com/actiniumpharma](http://www.twitter.com/actiniumpharma).

### **Forward-Looking Statements for Actinium Pharmaceuticals, Inc.**

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company, which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

### **Contact:**

#### **Actinium Pharmaceuticals, Inc.**

Steve O'Loughlin  
Principal Financial Officer  
[soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com)

Investor Relations  
Marek Ciszewski, J.D.  
949.574.3860  
ATNM@liolios.com



Source: Actinium Pharmaceuticals